001     859645
005     20240625095128.0
024 7 _ |a 10.3390/antib7030026
|2 doi
024 7 _ |a 2128/21828
|2 Handle
024 7 _ |a WOS:000448330700006
|2 WOS
037 _ _ |a FZJ-2019-00493
082 _ _ |a 540
100 1 _ |a Capelli, Riccardo
|0 P:(DE-Juel1)174546
|b 0
|u fzj
245 _ _ |a BPSL1626: Reverse and Structural Vaccinology Reveal a Novel Candidate for Vaccine Design Against Burkholderia pseudomallei
260 _ _ |a Basel
|c 2018
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1552413352_13869
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Due to significant advances in computational biology, protein prediction, together with antigen and epitope design, have rapidly moved from conventional methods, based on experimental approaches, to in silico-based bioinformatics methods. In this context, we report a reverse vaccinology study that identified a panel of 104 candidate antigens from the Gram-negative bacterial pathogen Burkholderia pseudomallei, which is responsible for the disease melioidosis. B. pseudomallei can cause fatal sepsis in endemic populations in the tropical regions of the world and treatment with antibiotics is mostly ineffective. With the aim of identifying potential vaccine candidates, we report the experimental validation of predicted antigen and type I fimbrial subunit, BPSL1626, which we show is able to recognize and bind human antibodies from the sera of Burkholderia infected patients and to stimulate T-lymphocytes in vitro. The prerequisite for a melioidosis vaccine, in fact, is that both antibody- and cell-mediated immune responses must be triggered. In order to reveal potential antigenic regions of the protein that may aid immunogen re-design, we also report the crystal structure of BPSL1626 at 1.9 Å resolution on which structure-based epitope predictions were based. Overall, our data suggest that BPSL1626 and three epitope regions here-identified can represent viable candidates as potential antigenic molecules.
536 _ _ |a 899 - ohne Topic (POF3-899)
|0 G:(DE-HGF)POF3-899
|c POF3-899
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Peri, Claudio
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Villa, Riccardo
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Nithichanon, Arnone
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Conchillo-Solé, Oscar
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Yero, Daniel
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Gagni, Paola
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Chiari, Marcella
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Lertmemongkolchai, Ganjana
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Cretich, Marina
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Daura, Xavier
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Bolognesi, Martino
|0 0000-0002-9253-5170
|b 11
700 1 _ |a Colombo, Giorgio
|0 P:(DE-HGF)0
|b 12
|e Corresponding author
700 1 _ |a Gourlay, Louise J.
|0 P:(DE-HGF)0
|b 13
|e Corresponding author
773 _ _ |a 10.3390/antib7030026
|g Vol. 7, no. 3, p. 26 -
|0 PERI:(DE-600)2661514-9
|n 3
|p 26 -
|t Antibodies
|v 7
|y 2018
|x 2073-4468
856 4 _ |y OpenAccess
|u https://juser.fz-juelich.de/record/859645/files/antibodies.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://juser.fz-juelich.de/record/859645/files/antibodies.pdf?subformat=pdfa
909 C O |o oai:juser.fz-juelich.de:859645
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)174546
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF3-890
|0 G:(DE-HGF)POF3-899
|2 G:(DE-HGF)POF3-800
|v ohne Topic
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2019
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
920 _ _ |l no
920 1 _ |0 I:(DE-Juel1)IAS-5-20120330
|k IAS-5
|l Computational Biomedicine
|x 0
980 1 _ |a FullTexts
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)IAS-5-20120330
981 _ _ |a I:(DE-Juel1)INM-9-20140121


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21